Condition

MDD

ClinicalTrials.gov condition label

Clinical trials41

Recruiting11

Common interventions25

Lead sponsors shown15

Clinical trials

41 shown

Inhaled DMT for Major Depressive DisorderNCT07562191 · 2026-08-01

tDCS: Sleep to Mood in Depression (S2M-D)NCT07572526 · 2026-06-04

Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD)NCT07111390 · 2025-08-18

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDDNCT06828887 · 2025-04-03

NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids StatusNCT07439744 · 2025-03-01

Psilocybin rTMS for Treatment Resistant DepressionNCT06132178 · 2025-01-10

At-Home tDCS as Maintenance TherapyNCT07269964 · 2024-10-01

Cancer Related Major Depression Treated With a Single Dose of PsilocybinNCT06319378 · 2024-04-19

Stress, Inflammation and Neuroimaging in Major Depressive Disorder as Compared to Premenstrual Dysphoric DisorderNCT06130371 · 2024-01-04

Efficacy of Statins Among Major Depressive DisorderNCT06698666 · 2022-10-01

Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in AdolescentsNCT05437588 · 2022-10-01

Individualized fMRI-guided TMS for DepressionNCT07804459 · 2026-09-15

NOT_YET_RECRUITING

Functional Electrical Stimulation for MDDNCT07629050 · 2026-05-25

NOT_YET_RECRUITING

Theta Burst Stimulation for Refractory Depression in Autism Spectrum DisorderNCT06670040 · 2024-09-16

ACTIVE_NOT_RECRUITING

Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness RegistryNCT06512324 · 2024-06-27

ENROLLING_BY_INVITATION

pBFS Guided rTMS Over Different Targets for Treatment-Resistant DepressionNCT06255561 · 2024-02-20

Resonant Frequency rTMS: A Novel Approach to Target Circuit Modulation in Major Depressive DisorderNCT06572683 · 2024-02-12

ENROLLING_BY_INVITATION

Take-home Functional Electrical Stimulation for MDDNCT06261177 · 2023-12-04

ACTIVE_NOT_RECRUITING

rTMS Therapy for Treatment-Resistant Depression With Different Targets Guided by pBFSNCT06095778 · 2023-11-06

pBFS-Guided rTMS Therapy Over Different Targets for Treatment-Resistant DepressionNCT05976009 · 2023-08-29

pBFS Guided VS "5-cm Rule" rTMS Over DLPFC for MDDNCT05964023 · 2023-08-20

pBFS Guided rTMS Therapy Over Different Targets for Treatment-Resistant DepressionNCT05976022 · 2023-08-04

Extended Reality Behavioral Activation: An Intervention for Major Depressive DisorderNCT05525390 · 2022-12-19

Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)NCT05657691 · 2022-11-28

The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)NCT04279522 · 2021-08-31

Mechanism of Action of tACS for the Treatment of MDDNCT03994081 · 2021-06-09

Effect of Magnesium Supplementation in Selective Serotonin Reuptake Inhibitors Treated Major Depressive Disorder PatientsNCT04880460 · 2021-03-18

Virtual Reality Behavioral Activation: An Intervention for Major Depressive DisorderNCT04268316 · 2020-05-18

Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive DisorderNCT04226352 · 2020-03-15

Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)NCT04220996 · 2019-12-27

Effect of Zinc Supplementation on Depression in SSRI-treated Major Depressive Disorder PatientsNCT04482296 · 2019-09-15

Maintenance Transcranial Magnetic Stimulation in Major Depressive DisorderNCT04076644 · 2019-09-01

Effect of Short-Term Mindfulness-Based Training For Major Depression Disorder: An Eye-Tracking StudyNCT04071886 · 2019-09-01

Effect of Vitamin D Administration Along With SSRIs in Patients With Major Depressive DisorderNCT03754712 · 2018-03-10

A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual InsomniaNCT02669030 · 2017-03-01

Transcranial Alternating Current Stimulation for Major Depressive DisorderNCT02339285 · 2015-05-07

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work EnvironmentNCT02013609 · 2013-11-01

Glutamatergic and GABAergic Mediators of Antidepressant Response in Major DepressionNCT01557946 · 2012-03-01

A Non Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient With Major Depressive Disorder (MDD)NCT01344733 · 2011-05-01

Evaluation of Generalization Paradigm Patterns Among Different Psychiatric DisordersNCT01501812 · 2011-03-01

A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive DisorderNCT01152554 · 2010-06-01

Common interventions

Leading sponsors

Changping Laboratory5 Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh3 AstraZeneca2 NYU Langone Health2 Stanford University2 Unity Health Toronto2 University of North Carolina, Chapel Hill2 Actinogen Medical1 Ain Shams University1 Biomedical Discoveries and Neuroscientific Foundations LLC1 Central South University1 Children's Hospital Medical Center, Cincinnati1 H. Lundbeck A/S1 Institute for Advanced Medical Research, Alpharetta, GA1 Johns Hopkins University1

Trial status mix

COMPLETED15

RECRUITING11

UNKNOWN9

ACTIVE_NOT_RECRUITING2

ENROLLING_BY_INVITATION2

NOT_YET_RECRUITING2

Phase mix

NA23

PHASE26

PHASE33

PHASE43

EARLY_PHASE11

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.